Robin L. Jones, BSc, MB BS, MRCP, MD

Consultant Medical Oncologist
Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, United Kingdom

Poster(s):

• (P 27) A MULTICENTER RETROSPECTIVE STUDY ON THE CLINICAL BEHAVIOR OF SDH-DEFICIENT GIST

• (P 40) LONG TERM OUTCOMES OF NEOADJUVANT IMATINIB AND SURGICAL RESECTION OF RECTAL GASTROINTESTINAL STROMAL TUMOURS

• (P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.

• (P 135) UNMET NEEDS IN LOCALLY ADVANCED (UNRESECTABLE) OR METASTATIC DEDIFFERENTIATED LIPOSARCOMA AND EXPECTATIONS FOR CLINICAL TRIALS: AN INTERNATIONAL DELPHI CONSENSUS STUDY

• (P 138) CONTROVERSIES IN THE MANAGEMENT OF PATIENTS WITH SOFT TISSUE SARCOMA: RESULTS AND RECOMMENDATIONS FROM THE FIRST CONFERENCE ON STATE OF SCIENCE IN SARCOMA (CSSS)

• (P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS

• (P 233) MULTI-CENTER EXTERNAL VALIDATION OF AN AUTOMATED MODEL DIFFERENTIATING ALT FROM LIPOMA USING RADIOMICS AND DEEP-LEARNING BASED SEGMENTATION

• (P 404) PROTEOMIC PROFILING OF THE SOFT TISSUE SARCOMA MICROENVIRONMENT IDENTIFIES A PROGNOSTIC SIGNATURE BASED ON PROTEOGLYCAN EXPRESSION AND CD8+ TUMOUR INFILTRATING LYMPHOCYTES

• (P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL

• (P 417) MULTI-OMIC CHARACTERISATION OF MOLECULAR HETEROGENEITY AND NEOADJUVANT THERAPY RESPONSE IN SYNOVIAL SARCOMAS

• (P 437) ULTRA-RARE UNDIFFERENTIATED SMALL ROUND CELL SARCOMA: HOW SHOULD WE TREAT THEM? AN ANALYSIS FORM THE GRACEFUL PROJECT

• (P 531) ENVASARC: A PIVOTAL TRIAL OF ENVAFOLIMAB AND ENVAFOLIMAB IN COMBINATION WITH IPILIMUMAB IN PATIENTS WITH ADVANCED OR METASTATIC UPS OR MFS WHO HAVE PROGRESSED ON PRIOR CHEMOTHERAPY

• (P 548) A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

• (P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN